Resilience and Mayo Clinic Announce Collaboration to Manufacture Biotherapeutics for Rare Diseases

Anna Osborne
16 August 2022
SHARE NOW
Cell Therapy
Collaborations, Mergers & Acquisitions
Finance & Investment
Gene Therapy
Technology-focused manufacturing company Resilience has announced it is to collaborate with the nonprofit organization Mayo Clinic to bio-manufacture and deliver novel biotherapeutics targeting rare and complex conditions.

Resilience and Mayo are to build embedded quality control, and, process and analytical development labs at Mayo’s Center for Regenerative Medicine within the research corridor of the Destination Medical Center economic development initiative in Rochester, Minnesota.

This will establish Rochester as a center for biomanufacturing regenerative technologies.

“Mayo is making significant investments in facilities to create the world’s most advanced and innovative ecosystem for the development, manufacture and delivery of biotherapeutics. We are seeking to build a community of innovators to explore ideas, develop new products and create thriving biotherapeutic companies,” comments Julie Allickson, Director of Mayo Clinic’s Center for Regenerative Medicine.

How are you enjoying this news article? Let us know your thoughts, here >>

These purpose-built facilities will allow the two companies to jointly develop biologically derived advanced therapies, including cell and gene therapies, into commercially ready products for the clinical care of complex and rare indications.

The collaboration will also see Resilience and Mayo work together to advance new biological discoveries into early-stage clinical trials – that will strive to attract sponsorship from third-party biotech companies. Additional sponsorship and collaboration from such companies will also be welcomed in the areas of process and analytical development.

Resilience will also bring their broad network, including 1 million square feet of biomanufacturing space over 11 facilities across North America, to the collaboration.

 

This space provides the capabilities to scale customer projects from the process and analytical stages, through preclinical and clinical, into commercial manufacturing, with additional capacity and capabilities at these sites to be added over the upcoming year.

The strategic collaboration allows Resilience to continue to build a sustainable network of high-tech end-to-end manufacturing solutions to make advanced therapies quickly, safely, and at scale, and, Mayo to maintain its commitment to advancing research, development, and the manufacturing of cell and gene therapies.

“By combining our organizations’ capabilities in biomanufacturing and medical innovation, we have an opportunity to deliver complex and innovative therapeutics to patients in need,” concludes Rahul Singhvi, Resilience CEO.

Source: Resilience Business Wire and Mayo Clinic Press Releases.


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.